Swedish Orphan Biovitrum AB has agreed to an additional Kineret drug campaign with Amgen.

Swedish Orphan Biovitrum AB has announced an agreement with Amgen to run an additional Kineret bulk drug campaign. In addition, Swedish Orphan Biovitrum will pay to buy-out previously agreed future sales milestones for Kineret and Kepivance. Under the agreement Amgen will run an additional Kineret campaign at its Boulder facility in CO, as well as manufacture drug product at its facility in Puerto Rico. The objective of this additional campaign is to meet an expected increased market demand of Kineret until Swedish Orphan Biovitrum has transferred manufacturing processes to new contract manufacturers. In …